Project Grant R21HL188524
Award Date 9/1/26
Completion Date 5/31/28
Dollars Obligated $231K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Emigration Canyon, UT 84108, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Massachusetts Medical School $858,456 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Assistance Listing R01HL184047) to develop and test an interoperable shared decision-making tool integrated into electronic health records for stroke prevention in atrial fibrillation patients. The project, titled DECIDE-AF, addresses suboptimal anticoagulation initiation and persistence among AF...
- The National Heart, Lung, and Blood Institute awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $823,576 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate an electronic health record-embedded shared decision-making intervention for improving statin prescribing and adherence in cardiovascular disease prevention. The recipient will conduct a randomized trial of CV Prevention Choice, a next-generation...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $2.815 million on September 24, 2025, under CFDA 93.837 (Cardiovascular Diseases Research) to conduct proteomic and genomic discovery of molecular targets linked to atrial cardiopathy-related cardiovascular outcomes. The award funds research using proteomics and genomic methods across primary and secondary prevention populations to identify novel proteins that may serve as causal risk factors for atrial...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $242,250 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 1, 2025 through June 30, 2027. This award funds research examining the relationship between atrial fibrillation (AF), oral anticoagulation therapy, and retinal stroke (central retinal artery occlusion) using an instrumental variable...
- The National Heart, Lung, and Blood Institute awarded the University of South Florida $2.186 million on September 19, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the relationship between atrial microvascular and endothelial dysfunction and postoperative atrial fibrillation. The research evaluates microvascular signaling pathways responsible for myogenic, vasomotor, and endothelial dysfunction of the atrial microvasculature in patients with...
- The National Heart Lung and Blood Institute awarded the University of Utah $367,200 on September 19, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolite transport modulation in myocardial ischemic-reperfusion injury. The research focuses on inhibition of monocarboxylate transporter 4 (MCT4), which regulates lactate excretion from cardiomyocytes, as a potential cardioprotective intervention following heart attack. The project comprises four specific...
- The National Heart Lung and Blood Institute awarded the University of Utah $470,606 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the molecular mechanisms of smoking-induced endothelial dysfunction associated with the ALDH2*2 genetic variant. The research employs a multidisciplinary approach integrating stem cell biology, molecular biology, toxicology, vascular physiology, and endothelial mechanobiology to understand how tobacco consumption...
- The National Heart, Lung, and Blood Institute awarded the University of Utah $231,000 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of lung megakaryocytes and lung megakaryocyte-derived platelets in lung injury. The research examines how platelets, which carry messenger RNA transcripts invested by parent megakaryocytes, contribute to coagulation and inflammatory immune responses in sepsis and acute respiratory distress syndrome...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $902,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an abbreviated cardiovascular magnetic resonance imaging solution for time-efficient, cost-effective etiology diagnosis of acute ischemic stroke. The project develops a 10-minute abbreviated cardiovascular MRI protocol designed to identify the underlying cause of acute ischemic...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $231,000 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a risk prediction tool for thromboembolism in heart failure patients without atrial fibrillation. The project will integrate clinical variables with cardiovascular magnetic resonance biomarkers to create the first comprehensive risk stratification score for incident ischemic stroke...